Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL.

Leukemia · 2018 · PMC5770586 · PMID 28592889

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a slight trendno p-value reported

25 Ibrutinib patients with mutated IGHV showed a slight trend to greater initial increase in absolute lymphocyte count (ALC) compared with those with unmutated IGHV ( Supplementary Figure 6 ), with apparent slower resolution in patients with mutated IGHV vs those with unmutated IGHV similar to a previous report ( P <0.001). 26 The best ORR increased in the ib

also in 4,078 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.